In the incretin-based therapies, both sitagliptin (DPP4 inhibitor) and exendin-4 (GLP-1 receptor agonist) are widely used to treat DM with glucose-lowering and anti-inflammatory effects22,33. Here, GLP1R is linked to diabetes mellitus.